Aperio Group LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 970,482 shares of the biopharmaceutical company’s stock after acquiring an additional 64,620 shares during the quarter. Aperio Group LLC owned about 0.07% of Gilead Sciences worth $69,525,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the company. Telemus Capital LLC bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $589,000. Kovack Advisors Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $2,023,000. First Western Capital Management Co boosted its position in shares of Gilead Sciences by 2.6% in the fourth quarter. First Western Capital Management Co now owns 37,548 shares of the biopharmaceutical company’s stock valued at $2,690,000 after acquiring an additional 949 shares during the period. Arlington Financial Advisors LLC bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $2,132,000. Finally, Harrington Investments INC boosted its position in shares of Gilead Sciences by 6.7% in the fourth quarter. Harrington Investments INC now owns 24,320 shares of the biopharmaceutical company’s stock valued at $1,742,000 after acquiring an additional 1,536 shares during the period. Institutional investors own 77.96% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $81.06 on Tuesday. The company has a market cap of $106,190.00, a P/E ratio of 10.54, a price-to-earnings-growth ratio of -1.86 and a beta of 1.24. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.67 and a current ratio of 2.74.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. This represents a $2.28 annualized dividend and a dividend yield of 2.81%. Gilead Sciences’s dividend payout ratio (DPR) is currently 27.05%.
In other news, insider John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the transaction, the insider now owns 3,046,766 shares in the company, valued at $224,302,912.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gayle E. Wilson sold 60,000 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the completion of the transaction, the director now owns 182,258 shares in the company, valued at approximately $14,201,543.36. The disclosure for this sale can be found here. Insiders sold 424,435 shares of company stock worth $33,602,330 in the last 90 days. Company insiders own 1.30% of the company’s stock.
A number of equities analysts have recently commented on the stock. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Credit Suisse Group set a $80.00 target price on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Wednesday, January 3rd. Leerink Swann lowered their target price on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 7th. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 target price on the stock in a research note on Monday, February 19th. Finally, Barclays reaffirmed an “overweight” rating and issued a $95.00 target price (up from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $87.75.
COPYRIGHT VIOLATION WARNING: “Aperio Group LLC Has $69.53 Million Stake in Gilead Sciences, Inc. (GILD)” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/03/13/aperio-group-llc-has-69-53-million-stake-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.